Mometasona Generis (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasona Generis, is a corticosteroid presented as an inhalation product for inhalation use. It reduces airway inflammation and hyperresponsiveness, and is indicated for the management of asthma and chronic obstructive pulmonary disease in adult patients.

GNH USA supplies Mometasona Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and distribution across multiple regions, including compliance with EU pharmacopoeial specifications.

Mometasona Generis, an inhaled corticosteroid, targets inflammatory pathways in chronic respiratory diseases.

Asthma: improves control of symptoms and reduces frequency of exacerbations. COPD: decreases airway inflammation and helps prevent disease worsening. Chronic bronchitis: alleviates cough and sputum production associated with airway inflammation.

Mometasona Generis may cause a range of adverse reactions, most of which are related to its local corticosteroid activity in the respiratory tract.

Common Side Effects: - Hoarseness or dysphonia. - Oral thrush (candidiasis). - Sore throat or irritation. - Cough. - Headache. - Nasal congestion.

Serious or Rare Side Effects: - Adrenal suppression. - Pneumonia or severe respiratory infection. - Cataracts or glaucoma. - Severe allergic reaction (anaphylaxis). - Immunosuppression leading to opportunistic infections. - Osteoporosis with long‑term high‑dose use.

Before prescribing Mometasona Generis, clinicians should consider several safety aspects.

Assess infection risk: evaluate for active respiratory infections before initiating therapy. Monitor growth in children: periodic assessment is recommended during long‑term use. Avoid abrupt discontinuation: taper the dose to prevent adrenal insufficiency. Use a spacer device: helps reduce oropharyngeal deposition and associated side effects. Avoid concomitant strong CYP3A4 inhibitors: may increase systemic exposure. Store at room temperature: keep in the original container, protect from moisture and light.

Mometasona Generis can interact with other medicines that affect corticosteroid metabolism or immune function.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase systemic exposure. - Systemic glucocorticoids: additive immunosuppressive effects and risk of adrenal suppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, ritonavir): may raise plasma levels modestly. - Theophylline: corticosteroids can enhance theophylline clearance, requiring dose adjustment. - Live vaccines: reduced efficacy; consider timing of vaccination relative to therapy.